About omalizuma b
Anti-IgE monoclonal antibody
Used for
- Add-on treatment for moderate to severe allergic asthma
- Chronic spontaneous hives not controlled by antihistamines
- Nasal polyps with chronic sinus inflammation
- IgE-mediated food allergy to reduce allergic reactions
Usual adult dose
Dose depends on condition, body weight, and blood IgE; given under the skin every 2 or 4 weeks.
Usual dose in children
For eligible children, dosing depends on condition, weight, and blood IgE; given under the skin every 2 or 4 weeks.
Common side effects
- Injection-site reactions
- Headache
- Joint or limb pain
- Rare severe allergic reaction
Important warnings
- Severe allergic reactions can occur, including after repeated doses.
- Treatment does not replace emergency treatment for sudden severe asthma or allergic reactions.
- Asthma treatment should not be stopped abruptly when starting this medicine.
- Monitor for symptoms of parasitic infection when exposure risk is high.
Pregnancy
Human pregnancy data are limited; use requires weighing potential benefits and risks.
Breastfeeding
It is not known whether clinically relevant amounts enter breast milk; discuss benefits and risks with a clinician.
Interactions
- No major drug interactions are established; tell the prescriber about all medicines.
AI-generated from general medical knowledge, not from this product's official leaflet. It may be incomplete or out of date. Not medical advice — ask a pharmacist or doctor before making any decision.